Press Releases Absci Corporation

Equities

ABSI

US00091E1091

Real-time Estimate Cboe BZX Other stock markets 10:54:23 2024-04-30 am EDT			5-day change	1st Jan Change
4.775 ^USD	-0.10%		-0.21%	+11.90%

Mar. 21	Earnings Flash (ABSI) ABSCI CORPORATION Reports Q4 Revenue $338,000	MT
Mar. 21	Absci Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024	Apr. 16	GL
Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024	Apr. 16	AQ
Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference	Mar. 28	GL
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results	Mar. 21	GL
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares	Mar. 01	GL
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares	Mar. 01	AQ
Absci Announces Pricing of Public Offering of Common Stock	Feb. 27	GL
Absci Announces Proposed Public Offering of Common Stock	Feb. 27	GL
Absci Announces Proposed Public Offering of Common Stock	Feb. 27	AQ
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI	Feb. 21	GL
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI	Feb. 21	AQ
Absci to Participate in Upcoming Investor Conferences	Feb. 20	GL
Absci Appoints Professor Sir Mene Pangalos to its Board of Directors	Jan. 10	GL
Absci Appoints Professor Sir Mene Pangalos to its Board of Directors	Jan. 10	AQ
Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference	Jan. 08	GL
Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference	Jan. 08	AQ
Absci to Participate in the 26th Annual Needham Growth Conference	Jan. 03	GL
Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 28	GL
Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 28	AQ
Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline	Dec. 20	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Absci Corporation

Equities

ABSI

US00091E1091

Press Releases

Filters